At what enterprise value was GLOBAL D acquired in 2024?

During the acquisition of GLOBAL D by NAXICAP PARTNERS in 2024, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 100M - 350M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of GLOBAL D when it was acquired by NAXICAP PARTNERS?

The estimated EV/EBITDA multiple for GLOBAL D is in the range of 15x - 25x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was GLOBAL D acquired by NAXICAP PARTNERS?

GLOBAL D was acquired by NAXICAP PARTNERS in 2024.

What was the revenue of GLOBAL D at the time of the deal?

The revenue of GLOBAL D at the time of the deal is estimated to be in the range of 25M - 50M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of GLOBAL D during the acquisition?

GLOBAL D's EBITDA is estimated to be in the range of 5M - 25M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the GLOBAL D acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the GLOBAL D deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.accuracy.com/global-d-sextrait-de-sa-maison-mere-cfnews/

← DATABASE

Home Database Healthcare & PharmaGLOBAL D

11/2024

GLOBAL D acquired by NAXICAP PARTNERS

FRANCE Life Sciences / Medical Devices / Implants & Prosthetics EV 100M - 350M EUR

Context

Naxicap Partners has acquired a majority stake (over 60%) in Global D, marking the company’s first independent LBO following its carve-out from the Menix Group. The remaining capital is held by a dozen managers led by the executive team. The transaction follows a competitive auction process and includes a financing package provided by Capza (unitranche and PIK debt) alongside a capex line from Banque Palatine. This strategic "independence" move follows the parent group's divestment of other assets to industrial giants. The rationale for this new cycle is to support the firm’s internationalization and active buy-and-build strategy, targeting niche acquisitions with revenues between 5 million and 20 million euros to complement its existing technology and geographic reach.

GLOBAL D, which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 2012 and based in Lyon, Global D is a leading French manufacturer of medical devices specializing in dental implantology and maxillofacial surgery. The company’s business model focuses on high-precision engineering and clinical support for over 15,000 clients, primarily private implantologists, dentists, and specialized surgical units in hospitals and clinics. Its product portfolio covers the entire range of dental reconstruction and facial bone repair. With a strong domestic leadership (70% of sales), the firm also operates subsidiaries in Poland and Italy and distributes its specialized medical devices in 30 countries globally. Its value proposition is built on technical innovation and deep expertise in the niche segment of bone integration and dental aesthetics.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
12/2024	UI INVESTISSEMENT	DIDACTIC	FRANCE	Life Sciences	Didactic reorganized its shareholder base to accelerate its transformation into a European industrial leader. GENEO Capital Entrepreneur and UI Investissement acquired a majority stake, taking over from the previous sponsor
12/2024	NEXTSTAGE / IK PARTNERS	EUROBIO SCIENTIFIC	FRANCE	Life Sciences	EB Development (Consortium: NextStage AM & IK Partners) has successfully concluded its takeover bid for Eurobio Scientific, following the results of a reopened offer period. The consortium now holds 88
10/2024	BANSK GROUP	PETIQ	UNITED STATES	Life Sciences	Bansk Group completed the acquisition of 100% of PetIQ in an all-cash public-to-private transaction. PetIQ was delisted from Nasdaq upon closing and is now operated as a privately held company, with founder Cord Christensen continuing as CEO
10/2024	CLAYTON, DUBILIER & RICE (CD&R)	OPELLA	FRANCE	Life Sciences	Sanofi has announced the sale of 50% of its stake in Opella to the American fund CD&R. Opella Healthcare (formerly Sanofi Consumer Healthcare) is a company specializing in consumer healthcare products
10/2024	KKR / KREFELD	ANJAC BEAUTY & HEALTH	FRANCE	Life Sciences	Anjac reorganized its capital by welcoming KKR and Krefeld as minority shareholders, following a competitive process led by Rothschild & Co. The EUR450M investment allowed the exit of historical partners Andera Partners, Bpifrance, and IDIA
09/2024	AGILENT TECHNOLOGIES	BIOVECTRA	CANADA	Life Sciences	Agilent Technologies has finalized the acquisition of BIOVECTRA, a move designed to fundamentally expand the group's contract development and manufacturing (CDMO) portfolio into fast-growing therapeutic modalities
08/2024	NORDSON CORPORATION	ATRION CORPORATION	UNITED STATES	Life Sciences	Nordson Corporation completed its acquisition of Atrion Corporation on August 21, 2024, following the definitive agreement announced on May 28, 2024. The strategic rationale is centered on portfolio expansion within Nordson Medical
08/2024	RECURSION PHARMACEUTICALS	EXSCIENTIA	UNITED KINGDOM	Life Sciences	Recursion Pharmaceuticals has entered into a definitive agreement to acquire Exscientia in an all-stock transaction. This strategic move aims to bring together two artificial intelligence-driven drug discovery specialists, creating a comprehensive platform that spans the entire process, from biology to computational chemistry
07/2024	ROCHE	LUMIRADX	UNITED KINGDOM	Life Sciences	The acquisition of the point-of-care technology platform from the LumiraDx group marks a transformative technical reinforcement of the acquirer's diagnostic ecosystem. The strategic rationale for this transaction centers on a "decentralization" play, merging the target's innovative multi-assay hardware with the group’s vast global commercial and R&D infrastructure
05/2024	BRUKER	ELITECH GROUP	FRANCE	Life Sciences	The successful acquisition of ELITechGroup by Bruker Corporation marks a definitive tactical expansion of the group's microbiology and infection diagnostics portfolio. This transaction facilitates the integration of ELITech’s innovative sample-to-result molecular diagnostic systems with Bruker’s existing microbial identification capabilities

REFERENCES

Valuation range: EV 100M - 350M EUR

Revenue range: 25M - 50M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of GLOBAL D by NAXICAP PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Acquirer: naxicap partners